Paragon Associates & Paragon Associates II Joint Venture’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Paragon Associates & Paragon Associates II Joint Venture’s Portfolio FOMX Stock Details FOMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,000	Closed	-$33K	–	21
2019 Q4	$33K	Buy	+10,000	New	+$31.8K	0.02%	19

Paragon Associates & Paragon Associates II Joint Venture's FOMX Position: Q1 2020 in Review

Paragon Associates & Paragon Associates II Joint Venture sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2020, closing a stake of 10,000 shares — an estimated $33K sold.

Paragon Associates & Paragon Associates II Joint Venture first reported a position in FOMX in Q4 2019 and held it in 1 quarter. The position peaked at $33K in Q4 2019. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.

Paragon Associates & Paragon Associates II Joint Venture reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2020 after selling out during the quarter.
Paragon Associates & Paragon Associates II Joint Venture sold 10,000 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2020, an estimated $33K.
Paragon Associates & Paragon Associates II Joint Venture first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q4 2019 and held it in 1 quarter.
Paragon Associates & Paragon Associates II Joint Venture's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $33K in Q4 2019.
3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2020.

Based on Paragon Associates & Paragon Associates II Joint Venture's 13F filing for Q1 2020, filed 15 May 2020.